This is a working overview of pentapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-22 and is reviewed periodically as new material appears.
Selectivity distinguishes ipamorelin from first-generation secretagogues such as GHRP-6. At doses that reliably raise growth hormone, it shows little stimulation of adrenocorticotropic hormone or cortisol release in animal models, and it does not markedly raise prolactin or appetite. Binding at GHS-R1a on pituitary somatotrophs triggers calcium influx and pulsatile growth hormone secretion. Because the compound mimics the natural ghrelin signal, the release pattern tends to follow the body's own rhythm rather than producing a sustained elevation.
Most published work on ipamorelin comes from rodent studies and small early-phase human trials. Subcutaneous and intravenous routes have been used, while oral delivery is limited by poor absorption and rapid breakdown in the gut. The reported plasma half-life is short, on the order of two hours, and varies with species and assay method. Whether chronic use produces meaningful clinical benefit remains unresolved, and long-term safety data in humans are sparse. No major regulatory agency has approved the compound as a therapeutic drug.
Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue family. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, incorporating two non-natural residues that resist enzymatic breakdown. Researchers at Novo Nordisk described the compound in the 1990s while searching for agents that release growth hormone with fewer side effects than earlier secretagogues. The molecule acts as an agonist at the ghrelin receptor, also called GHS-R1a, which is expressed in the pituitary and in several peripheral tissues.
Ipamorelin 是一种合成五肽，序列为 Aib-His-D-2-Nal-D-Phe-Lys-NH2，分子式 C38H49N9O5，游离碱分子量约 711.85 g/mol。它属于生长激素促分泌素（GHS）家族，作用靶点是胃饥饿素受体 GHS-R1a。该化合物由诺和诺德的研究团队在二十世纪九十年代末报道，设计目标是提高对生长激素释放的选择性。C 端酰胺化与 N 端 Aib 残基是两个用于抵抗肽酶降解的结构特征。
在 GHS 家族中，早期肽类如 GHRP-6 与 GHRP-2 会同时促进生长激素、皮质醇与催乳素的释放，并明显增加食欲。Ipamorelin 在动物与早期人体研究中表现出对生长激素释放的相对选择性，对上述其他激素的影响较小。这种差异通常归因于受体结合模式与下游信号偏向的不同，而完整的分子解释仍有待补充。需要区分的是，选择性是研究观察中的相对程度，并非绝对界限。
从用途定位看，ipamorelin 目前主要以研究用肽的身份被讨论，未见主要药品监管机构将其批准为治疗药物。市售材料通常标注仅供研究使用，不得用于人体或诊断程序。文献中它常与生长激素促分泌素、GHS-R1a 激动剂、胃饥饿素拟似物等表述并列出现。既有研究的样本量普遍偏小，因此对其效应强度与一致性的描述应保持谨慎。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H49N9O5 | Includes two non-natural residues |
| Molecular weight | About 711.9 g/mol | Confirmed by mass spectrometry |
| Appearance | White to off-white powder | Typical lyophilized form |
| Receptor target | GHS-R1a | Ghrelin receptor agonist |
| Plasma half-life | Roughly 2 hours | Varies by species and assay |
Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.
At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.
One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.
Ipamorelin is a synthetic pentapeptide classified as a growth hormone secretagogue. Its sequence, Aib-His-D-2-Nal-D-Phe-Lys-NH2, combines three non-proteinogenic residues with a C-terminal amide. The N-terminal aminoisobutyric acid unit and the two aromatic D-amino acids distinguish it from peptides assembled only from standard L-amino acids. Its formula is C38H49N9O5, corresponding to an average mass near 711.9 Da. At neutral pH the molecule carries a net positive charge, a property that shapes its behaviour in chromatographic and electrophoretic systems.
The compound was developed at Novo Nordisk during the 1990s as part of a programme seeking secretagogues with improved selectivity. It was described in the peer-reviewed literature in 1998 alongside related pentapeptides from the same series. Investigators advanced it because it raised growth hormone output in animal models while leaving other pituitary hormones comparatively unaffected. The development code NNC 26-0161 appears in earlier reports, and ipamorelin later became the common designation in published work.
Ipamorelin 是一种合成五肽，在 20 世纪 90 年代被报道为生长激素促分泌剂。其结构基于胃饥饿素受体激动剂的设计思路，但并非天然激素。早期药理学研究显示，它可刺激垂体释放生长激素，而对应激激素轴的影响相对较小。该化合物常被用作研究生长激素调节通路的工具分子。
在机制层面，ipamorelin 与生长激素促分泌受体 1a 型结合，该受体也介导胃饥饿素的多种效应。受体激活后，细胞内信号促进生长激素从垂体前叶释放。由于对促肾上腺皮质激素和皮质醇的刺激较弱，它被视为选择性较高的促分泌剂。这种选择性在动物模型和少量人体研究中被观察到，但人体数据仍然有限。
Annex II to the Convention on the Physical Protection of Nuclear Material 1980 (which became operative on 8 February 1997) classifies DU as a category II nuclear material. Storage and transport rules are set down for that category which indicates that DU is considered sufficiently "hot" and dangerous to warrant these protections. But since weapons containing DU are relatively new weapons no treaty exists yet to regulate, limit or prohibit its use. The legality or illegality of DU weapons must therefore be tested by recourse to the general rules governing the use of weapons under humanitarian and human rights law which have already been analysed in Part I of this paper, and more particularly at paragraph 35 which states that parties to Protocol I to the Geneva Conventions of 1949 have an obligation to ascertain that new weapons do not violate the laws and customs of war or any other international law. As mentioned, the International Court of Justice considers this rule binding customary humanitarian law. Louise Arbour, chief prosecutor for the International Criminal Tribunal for the Former Yugoslavia led a committee of staff lawyers to investigate possible treaty prohibitions against the use of DU in weapons. Their findings were that:
A lithium-ion battery or Li-ion battery is a type of rechargeable battery that uses the reversible intercalation of lithium ions (Li+) into electronically conducting solids to store energy. There are many different varieties, which are usually categorized by the materials used in the cathode. Compared to other rechargeable battery types, they generally have higher specific energy, energy density, and energy efficiency and a longer cycle life and calendar life. In the three decades since Li-ion batteries were first sold in 1991, their volumetric energy density increased threefold while their cost dropped tenfold. In late 2024, global demand passed 1 terawatt-hour per year, while production capacity was more than twice that. The invention and commercialization of Li-ion batteries has had a large impact on technology, as recognized by the 2019 Nobel Prize in Chemistry, which was awarded to contributors to the development of Li-ion batteries. Li-ion batteries have enabled portable consumer electronics, laptop computers, cellular phones, and electric cars. They are used for grid-scale energy storage and in military and aerospace applications. Li-ion battery sizes are generally not standardised (e.g. in the spirit of the AA battery) and they come in various and unique form factors depending on device and vendor. They typically have a nominal voltage of 3.6 or 3.7 V. M.
still holds, the surface energy (γ) predicted by Griffith's theory is usually unrealistically high. A group working under G. R. Irwin at the U.S. Naval Research Laboratory (NRL) during World War II realized that plasticity must play a significant role in the fracture of ductile materials. In ductile materials (and even in materials that appear to be brittle), a plastic zone develops at the tip of the crack. As the applied load increases, the plastic zone increases in size until the crack grows and the elastically strained material behind the crack tip unloads. The plastic loading and unloading cycle near the crack tip leads to the dissipation of energy as heat. Hence, a dissipative term has to be added to the energy balance relation devised by Griffith for brittle materials. In physical terms, additional energy is needed for crack growth in ductile materials as compared to brittle materials. Irwin's strategy was to partition the energy into two parts:
Sources: en.wikipedia.org
Schiller (1969), lawyer, co-founder of Boies Schiller Flexner LLP Eric Eisner (1970), lawyer, former president of The Geffen Company and founder of the Young Eisner Scholars program William Barr (1971), attorney general of the United States Arthur Engoron (1971), judge presiding over the New York civil investigation of The Trump Organization Arthur Helton (1971), lawyer, refugee advocate Gerard E. Lynch (1972), judge of the United States District Court for the Southern District of New York Gary Stephen Katzmann (1973), judge on the United States Court of International Trade Robert Katzmann (1973), judge of the United States Court of Appeals for the Second Circuit Eric Holder (1973), United States attorney general under Barack Obama, deputy attorney general under Bill Clinton, United States Attorney for the District of Columbia, judge of the Superior Court of the District of Columbia Jonathan Cuneo (1974), lawyer, founding partner of Cuneo Gilbert & LaDuca, LLP Abbe Lowell (1974), partner at Chadbourne & Parke, chief minority counsel during the Impeachment of Bill Clinton Jeffrey L. Kessler (1975), co-chairman of Winston & Strawn; former global litigation chair at Dewey & LeBoeuf Douglas Letter (1975), general counsel to the United States House of Representatives since 2018 J. Richard Cohen (1976), former president of the Southern Poverty Law Center Joseph A. Greenaway Jr.
== References == 11. Website publication of Silver Book: The Silver Book and the NPU Format for Clinical Laboratory Science Reports Regarding Properties, Units, and Symbols . Published Online: 2017-04-25; Published in Print: 2017-04-25
This distorts the shape of the red blood cell, resulting in the characteristic "sickle" shape, and reduces cell flexibility. This rigid, distorted red blood cell can accumulate in blood vessels creating a blockage. The blockage prevents blood flow to tissues and can lead to tissue death which causes great pain to the individual.
Sources: en.wikipedia.org
The peptide is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Two of its residues are non-natural, which slows enzymatic degradation. The C-terminal amide is common among bioactive peptides.
It binds the same ghrelin receptor but with greater selectivity in functional assays. Preclinical work reports less cortisol and prolactin stimulation at growth-hormone-releasing doses. Those differences are relative, not absolute, and depend on dose and model.
No major regulatory authority has approved it for human therapeutic use. It is sold as a research chemical for laboratory investigation. Clinical status varies by country and is subject to change.
两者都是 GHS-R1a 激动剂，但 ipamorelin 在研究中显示出更高的生长激素释放选择性。早期资料显示它对皮质醇、催乳素与食欲的刺激弱于 GHRP-6。这些差异是相对程度，而非绝对区分。